Drugs Used in Pulmonary Hypertension — MCQs
Intravenous furosemide is used for rapid control of symptoms in acute left ventricular failure. It provides quick relief of dyspnoea by :
Which of the following drugs can be given in patients of primary pulmonary hypertension?
Which of the following is not typically seen on a chest X-ray in pulmonary artery hypertension?
In patients taking tadalafil, the most serious drug interaction occurs with:
Which ACE inhibitor is safe in renal failure?
Which of the following is the best inotrope agent for use in right heart failure secondary to pulmonary hypertension?
Regarding furosemide, which statement is true?
Which of the following medications is not typically used for the treatment of erectile dysfunction?
An induction agent of choice for poor-risk patients with cardiorespiratory disease as well as in situations where preservation of a normal blood pressure is crucial:-
Which of the following is a PGE1 analogue used in medical treatments?
Drugs Used in Pulmonary Hypertension Indian Medical PG Practice Questions and MCQs
Question 1: Intravenous furosemide is used for rapid control of symptoms in acute left ventricular failure. It provides quick relief of dyspnoea by :
- A. Causing venodilation (Correct Answer)
- B. Producing bronchodilation
- C. Stimulating left ventricular contractility
- D. Causing rapid diuresis and reducing circulating blood volume
Explanation: ***Causing venodilation*** - Furosemide, even before significant diuresis, causes rapid **venodilation**, leading to a decrease in **preload** and pulmonary congestion. This reduces the work of the heart and alleviates dyspnoea. - This effect is mediated by the release of **prostaglandins** and is observed within minutes of intravenous administration. *Producing bronchodilation* - Furosemide does not directly cause bronchodilation; it primarily acts on the kidneys and vasculature. - While improved pulmonary edema can secondarily ease breathing, its quick relief of dyspnoea is not due to direct airway relaxation. *Stimulating left ventricular contractility* - Furosemide is a loop diuretic and does not directly enhance **myocardial contractility**; it is not an inotropic agent. - In fact, by reducing preload and afterload, it can indirectly reduce the immediate demand on the failing ventricle. *Causing rapid diuresis and reducing circulating blood volume* - While furosemide does cause rapid diuresis and a reduction in circulating blood volume, these effects typically take longer to fully manifest (around 30 minutes to an hour) when compared to the immediate relief of dyspnoea seen after IV administration. - The initial rapid relief of dyspnoea is attributed more to its vasodilatory properties, reducing cardiac preload.
Question 2: Which of the following drugs can be given in patients of primary pulmonary hypertension?
- A. Icatibant
- B. Bosentan (Correct Answer)
- C. Sodium nitroprusside
- D. Labetalol
Explanation: ***Bosentan*** - **Bosentan** is an **endothelin receptor antagonist** that blocks the vasoconstrictive and proliferative effects of endothelin-1, a key mediator in the pathogenesis of **pulmonary hypertension**. - It is an FDA-approved medication specifically used for the treatment of **pulmonary arterial hypertension (PAH)**, improving exercise capacity and delaying clinical worsening. *Icatibant* - **Icatibant** is a **bradykinin B2 receptor antagonist** used in the treatment of **hereditary angioedema**. - It has no known role or efficacy in the management of **primary pulmonary hypertension**. *Labetalol* - **Labetalol** is a **beta-blocker** with **alpha-1 adrenergic blocking activity** used primarily for systemic **hypertension** and **hypertensive emergencies**. - Beta-blockers are generally **contraindicated** in pulmonary hypertension as they can worsen right heart function and lead to clinical deterioration. *Sodium nitroprusside* - **Sodium nitroprusside** is a **direct arterial and venous vasodilator** used in hypertensive crises and severe heart failure by reducing both preload and afterload. - While it can lower systemic blood pressure, its use in pulmonary hypertension is **limited** due to the risk of **systemic hypotension** and the lack of selective pulmonary vasodilation compared to other agents.
Question 3: Which of the following is not typically seen on a chest X-ray in pulmonary artery hypertension?
- A. Enlargement of central arteries
- B. Peripheral pruning
- C. Narrowing of central arteries (Correct Answer)
- D. None of the options
Explanation: ***Narrowing of central arteries*** - **Pulmonary artery hypertension** is characterized by the **enlargement of the central pulmonary arteries** due to increased pressure. - **Narrowing of central arteries** would contradict the hemodynamic changes seen in pulmonary hypertension. - This is the finding that is **NOT typically seen**, making this the correct answer. *Enlargement of central arteries* - This is a **hallmark radiographic finding** in pulmonary hypertension, reflecting the **dilatation of the main and proximal pulmonary arteries** due to increased pressure. - The **pulmonary artery segment becomes prominent**, often appearing convex on the left heart border. *Peripheral pruning* - This refers to the **abrupt tapering and loss of peripheral pulmonary vascular markings**, indicating reduced blood flow to the distal lung parenchyma. - It is a **common finding in advanced pulmonary hypertension**, as the distal vessels constrict and become obliterated. *None of the options* - This is incorrect since **narrowing of central arteries** is clearly not a typical finding in pulmonary hypertension.
Question 4: In patients taking tadalafil, the most serious drug interaction occurs with:
- A. Alpha-Blockers
- B. Ketoconazole
- C. Rifampicin
- D. Nitrates (Correct Answer)
Explanation: ***Nitrates*** - The co-administration of **tadalafil** (a PDE5 inhibitor) with **nitrates** can cause a dangerous and potentially fatal drop in **blood pressure**. - Both drug classes lead to increased cGMP levels, resulting in excessive **vasodilation** and profound **hypotension**. *Alpha-Blockers* - Alpha-blockers, while able to cause **hypotension** when taken with tadalafil, generally lead to less severe interactions than nitrates. - The combination requires caution and potentially dose adjustments, but typically does not result in the same life-threatening blood pressure drops as seen with nitrates. *Ketoconazole* - **Ketoconazole** is a strong **CYP3A4 inhibitor**, which can increase the plasma concentration of tadalafil. - This interaction can potentiate tadalafil's effects and increase the risk of side effects, but it doesn't create an immediate, life-threatening hypotensive crisis like nitrates. *Rifampicin* - **Rifampicin** is a potent **CYP3A4 inducer**, which can significantly decrease the plasma concentration of tadalafil. - This interaction primarily leads to a **reduced efficacy** of tadalafil, rather than a dangerous increase in adverse effects or a severe drug-drug interaction.
Question 5: Which ACE inhibitor is safe in renal failure?
- A. Captopril
- B. Enalapril
- C. None of the options
- D. Benazepril (Correct Answer)
Explanation: ***Benazepril*** - Among the listed ACE inhibitors, benazepril has the **most favorable excretion profile** in renal failure with approximately **50% renal and 50% hepatic elimination** (dual excretion pathway). - This balanced elimination reduces the risk of drug accumulation compared to predominantly renally excreted ACE inhibitors. - While dose adjustment may still be needed in **severe renal impairment**, benazepril is considered the **safest option among those listed** for patients with renal dysfunction. - **Note:** Fosinopril (not listed here) has true 50/50 dual elimination and requires no dose adjustment in renal failure, making it the ideal choice in clinical practice. *Captopril* - This ACE inhibitor undergoes predominantly **renal excretion (95%)** as unchanged drug and metabolites. - Requires significant **dose reduction** in renal failure to prevent accumulation and adverse effects including **hyperkalemia** and **hypotension**. - Less safe than benazepril in renal impairment due to heavy dependence on renal elimination. *Enalapril* - Enalapril is a prodrug converted to **enalaprilat**, with approximately **90% renal excretion**. - Dose adjustment is mandatory based on **creatinine clearance** in patients with renal failure. - Higher risk of accumulation and toxicity compared to dual-elimination ACE inhibitors like benazepril.
Question 6: Which of the following is the best inotrope agent for use in right heart failure secondary to pulmonary hypertension?
- A. Milrinone (Correct Answer)
- B. Dobutamine
- C. Digoxin
- D. Dopamine
Explanation: ***Milrinone*** - Milrinone is a **phosphodiesterase-3 inhibitor** that increases myocardial contractility and causes **pulmonary and systemic vasodilation**. - Its vasodilatory effect is particularly beneficial in **pulmonary hypertension** as it can help reduce **pulmonary vascular resistance (PVR)**, a critical factor in right heart failure. - The combination of **positive inotropy** and **selective pulmonary vasodilation** makes it the optimal choice for right ventricular failure secondary to pulmonary hypertension. *Dobutamine* - Dobutamine is a **beta-1 agonist** that primarily increases myocardial contractility with some beta-2 mediated vasodilation. - While it improves cardiac output, its lesser effect on **pulmonary vascular resistance** compared to milrinone makes it less ideal for right heart failure specifically complicated by pulmonary hypertension. *Digoxin* - Digoxin is a **cardiac glycoside** that increases contractility but has a slow onset of action and a narrow therapeutic window, making it less suitable for acute management. - It does not significantly reduce **pulmonary vascular resistance** and is primarily used for chronic heart failure or rate control in atrial fibrillation. *Dopamine* - Dopamine is a **catecholamine** with dose-dependent effects: at moderate doses (5-10 mcg/kg/min), it acts as a **beta-1 agonist** providing inotropic support. - However, at higher doses it causes **alpha-adrenergic vasoconstriction** which can **increase pulmonary vascular resistance**, potentially worsening right heart failure in pulmonary hypertension. - Unlike milrinone, it lacks specific pulmonary vasodilatory properties beneficial for reducing RV afterload.
Question 7: Regarding furosemide, which statement is true?
- A. Acute pulmonary edema is an indication (Correct Answer)
- B. Primarily administered via the oral route
- C. Causes diuresis by acting on the distal tubule
- D. Acts on the collecting duct
Explanation: ***Acute pulmonary edema is an indication*** - **Furosemide** is a potent diuretic frequently used to treat **acute pulmonary edema** due to its rapid onset of action and significant diuretic effect. - It helps reduce systemic and pulmonary congestion by promoting the excretion of excess fluid. *Primarily administered via the oral route* - While furosemide can be administered orally, in acute and severe conditions like **pulmonary edema**, it is often given **intravenously** for a faster and more potent effect. - Oral administration is more common for chronic management of fluid retention, but not the primary route for acute, life-threatening situations where rapid action is needed. *Causes diuresis by acting on the distal tubule* - Furosemide is a **loop diuretic** that primarily acts on the **thick ascending limb of the loop of Henle**, not the distal tubule. - It inhibits the **Na+-K+-2Cl- cotransporter** in this segment, leading to significant diuresis. *Acts on the collecting duct* - Diuretics that act on the **collecting duct** primarily include **potassium-sparing diuretics** like spironolactone and amiloride, which work differently from furosemide. - Furosemide's main site of action is earlier in the nephron, at the **loop of Henle**.
Question 8: Which of the following medications is not typically used for the treatment of erectile dysfunction?
- A. Beta blockers (Correct Answer)
- B. Papaverine
- C. Sildenafil
- D. PG-E
Explanation: ***Beta blockers*** - **Beta blockers** are primarily used to treat conditions like **hypertension** and **heart disease**. - While they can cause ED as a side effect, they are **not used for its treatment**. *Sildenafil* - **Sildenafil** is a **PDE5 inhibitor** that works by increasing **blood flow to the penis**, facilitating an erection. - It is a **first-line oral medication** widely prescribed for erectile dysfunction. *PG-E* - **PG-E** refers to **Prostaglandin E1** (alprostadil), which can be administered via **intracavernosal injection** or **urethral suppository**. - It directly causes **vasodilation** in the penis, leading to an erection, and is used when oral medications are ineffective or contraindicated. *Papaverine* - **Papaverine** is a **non-specific vasodilator** that can be used as an **intracavernosal injection** for ED. - It works by relaxing **smooth muscle** in the penile arteries, increasing blood flow and inducing an erection, often used in combination with phentolamine.
Question 9: An induction agent of choice for poor-risk patients with cardiorespiratory disease as well as in situations where preservation of a normal blood pressure is crucial:-
- A. Ketamine
- B. Etomidate (Correct Answer)
- C. Propofol
- D. Thiopentone
Explanation: ***Etomidate*** - Etomidate is preferred in patients with **cardiac disease** or **hemodynamic instability** due to its minimal effects on cardiovascular function. - It maintains **cardiovascular stability**, including myocardial contractility and blood pressure, making it ideal for procedures where maintaining a normal blood pressure is crucial. *Ketamine* - Ketamine often causes a **sympathetic stimulating effect**, leading to increases in heart rate and blood pressure, which may be detrimental in such patients. - It is associated with **tachycardia** and **hypertension**, undesirable in a poor-risk patient with cardiorespiratory disease. *Propofol* - Propofol is a potent **vasodilator** and myocardial depressant, which can lead to significant **hypotension**, especially in volume-depleted or critically ill patients. - Its use can result in a dose-dependent decrease in **arterial blood pressure** and **cardiac output**. *Thiopentone* - Thiopentone can cause **myocardial depression** and significant **hypotension**, especially in patients with compromised cardiovascular function. - It leads to a notable decrease in **vascular tone** and venous return, thus lowering blood pressure.
Question 10: Which of the following is a PGE1 analogue used in medical treatments?
- A. Carboprost
- B. Alprostadil (Correct Answer)
- C. Epoprostenol
- D. Dinoprostone
Explanation: ***Alprostadil*** - **Alprostadil** is a synthetic **prostaglandin E1 (PGE1)** analogue. - It is used in neonates to maintain the **patency of the patent ductus arteriosus** and in adults for the treatment of **erectile dysfunction**. *Carboprost* - **Carboprost** is a synthetic analogue of **prostaglandin F2 alpha (PGF2α)**. - It is primarily used to manage **postpartum hemorrhage** due to its potent uterotonic effects. *Epoprostenol* - **Epoprostenol** is a synthetic analogue of **prostacyclin (PGI2)**. - It is known for its potent **vasodilatory** and **antiplatelet** properties, making it useful in treating **pulmonary arterial hypertension**. *Dinoprostone* - **Dinoprostone** is a synthetic form of **prostaglandin E2 (PGE2)**. - It is used to **induce labor** or **cervical ripening** due to its role in uterine contractions and cervical dilation.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free